Stryker (NYSE: SYK) is one of 19 publicly-traded companies in the “Medical Devices & Implants” industry, but how does it weigh in compared to its peers? We will compare Stryker to similar companies based on the strength of its valuation, risk, analyst recommendations, profitability, dividends, earnings and institutional ownership.
Valuation and Earnings
This table compares Stryker and its peers revenue, earnings per share (EPS) and valuation.
Stryker has higher revenue and earnings than its peers. Stryker is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Stryker pays an annual dividend of $1.70 per share and has a dividend yield of 1.1%. Stryker pays out 36.3% of its earnings in the form of a dividend. As a group, “Medical Devices & Implants” companies pay a dividend yield of 1.3% and pay out 39.8% of their earnings in the form of a dividend. Stryker has increased its dividend for 6 consecutive years.
This is a summary of recent recommendations and price targets for Stryker and its peers, as reported by MarketBeat.com.
||Strong Buy Ratings
Stryker presently has a consensus target price of $152.37, suggesting a potential upside of 0.81%. As a group, “Medical Devices & Implants” companies have a potential upside of 41.23%. Given Stryker’s peers stronger consensus rating and higher possible upside, analysts plainly believe Stryker has less favorable growth aspects than its peers.
Insider and Institutional Ownership
75.0% of Stryker shares are owned by institutional investors. Comparatively, 54.8% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 7.4% of Stryker shares are owned by company insiders. Comparatively, 10.3% of shares of all “Medical Devices & Implants” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Risk and Volatility
Stryker has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500. Comparatively, Stryker’s peers have a beta of 0.47, suggesting that their average share price is 53% less volatile than the S&P 500.
This table compares Stryker and its peers’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Stryker beats its peers on 9 of the 15 factors compared.
Stryker Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products. The MedSurg segment includes surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment, intensive care disposable products; reprocessed and remanufactured medical devices, and other related products. The Neurotechnology and Spine segment includes neurovascular products, spinal implant systems and other related products. The Company’s products include implants, which are used in joint replacement and trauma surgeries, and other products that are used in a range of medical specialties.
Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.